Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom



Survival: 12.7 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
Hormone
   
Drugs:
Country: United Kingdom
   
City/State/Province: Sutton, Surrey
   
Hospital: Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
   
Journal: Link
   
Date: 10/2010

Description:
Patients:
This phase 3 study involved men with metastatic castration-resistant prostate cancer. Patients were separated into two treatment groups. Group A consisted of 377 men with a median age of 67 years and a range of 61-72. Group B included 378 men with a median age of 68 years and a range of 62-73.

Treatment:
Patients in group A were given the hormone prednisone (to act as an anti-inflammatory medication) along with the chemotherapy agent mitoxantrone, which targets DNA replication to block cancer cell growth.

Patients in group B were given the hormone prednisone and the chemotherapy agent cabazitaxel, which is a microtubule-stabilizer that blocks division (growth) of cancer cells.

Toxicities:
Three deaths due to adverse events were reported for group A. Causes included neutropenia/sepsis, cardiac event, and motor vehicle accident. Neutropenia (58% of patients), leucopenia (42%), and anemia (5%) were the most common toxicities of grade 3 or higher.

In group B, 18 deaths due to adverse events were reported. Causes included neutropenia/sepsis, cardiac events, dehydration/electrolyte imbalance due to diarrhea, renal failure, and cerebral hemorrhage.

Results:
Median progression-free survival for group A (mitoxantrone) was 1.4 months and median overall survival was 12.7 months.

For group B (cabazitaxel), the median progression-free survival was 2.8 months and the median overall survival was 15.1 months.

Support:
This study was funded by Sanofi-Aventis, makers of mitoxantrone.

Correspondence: Dr. Johann Sebastian de Bono; email: johann.de-bono@icr.ac.uk

E-mail to a Friend Email Physician More Information